compounding pharmacy glp-1 enforcement news today FDA is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified FDA Escalates Enforcement Against Compounded

Use CANVA to Repurpose the Templates For Various Uses

Farxiga can cost up to $600 without insurance, depending on the pharmacy and brand choice

#retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP-1 receptor

The SELECT study with semaglutide will report results only in 2023 and tirzepatide is being tested in patients with diabetes in the SURPASS-CVOT

This systematic review aims to synthesize existing evidence on the effects of GLP-1 RAs on mental health outcomes, including both potential therapeutic benefits across various psychiatric disorders and the risk of associated adverse mental health effects